Your Health, We Care
Takeda announced the TOURMALINE-MM3 Phase 3 trial, which targets patients with multiple myeloma. Currently, Ixazomib has not been approved as a maintenance therapy for multiple myeloma.
TOURMALINE is a comprehensive clinical research and development program for Isuzomi, which includes a total of six ongoing critical trials - five are studying each major multiple myeloma patient population, and one is studying light chain amyloidosis.
